21 results
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 21
Results of Operations and Financial Condition
4:31pm
Pluripotent MoA Well Tolerated Confirmed Target Engagement GB0139: Inhalable, Once-Daily Treatment for IPF Potential for Accelerated Approval 8
Phase 1 … Result - Bioavailability & Target Engagement in IPF Patients 11 Exceptionally Consistent PK Data in IPF Patients GB0139 Reaches the Alveolar
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
Superior Delivery Pluripotent MoA Confirmed Target Engagement Indications of Efficacy GB0139: Inhalable, once-daily treatment for IPF Potential … ) obtained for all 48 bronchoscopies 11
GB0139: Phase 2a result - Bioavailability & target engagement in IPF patients Exceptionally Consistent PK
8-K
EX-99.1
GLTO
Galecto Inc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
on Standard of Care
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung … breathless, all patients were able to effectively inhale GB0139 and achieve pharmacologically relevant plasma levels. Target engagement was confirmed
8-K
GLTO
Galecto Inc
21 Dec 23
Other Events
4:30pm
target engagement systemically by binding to lysyl oxidase-like 2 (LOXL2) in plasma.
All six patients who experienced a 1-grade reduction in bone
8-K
GLTO
Galecto Inc
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
3 mg arms, and thus there was no confirmation of target engagement in the trial. The mean change in FVC from baseline to week 52 was -316.6 ml
8-K
EX-99.1
8cl7vjhm9gtr4
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
hrmcm6c0vxrycbhmt
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
PRE 14A
zz77h lnw4pr
16 Apr 24
Preliminary proxy
4:00pm
S-1/A
EX-10.4
yhhzx
22 Oct 20
IPO registration (amended)
6:13am
S-1/A
EX-10.5
7gxgdn 13
22 Oct 20
IPO registration (amended)
6:13am
DEF 14A
3wfeodvi2vxs
14 Apr 21
Definitive proxy
7:00am